AVITA Medical Inc
AVITA Medical Reports Accelerating Grafting Times in Positive Interim Results for Cohealyx-I Study
AVITA Medical reports Cohealyx-I interim: mean grafting 13.6 days vs 33.2 benchmark; early grafting, strong clinician adoption signals.
AVITA Medical to launch RECELL GO system in US burn centres following FDA approval
Wound care management specialist AVITA Medical (ASX: AVH) has obtained US Food and Drug Administration (FDA) approval for its RECELL GO skin restoration system. RECELL GO is a cell-harvesting device that utilises the regenerative properties of a patient’s own skin to treat thermal burn wounds and full-thickness skin defects. Chief executive officer Jim Corbett said […]
What are the ASX stocks vulnerable to a ‘short squeeze’?
Could the ASX become subject to the same trading shenanigans in the US which put a rocket up the share price of struggling video outlet operator GameStop and then the silver market. It’s certainly food for short … er, thought. This month shares in online travel agent Webjet (ASX: WEB) have climbed around 10% as […]
Avita Medical enrols first patients in studies evaluating RECELL system
Regenerative medicine company Avita Medical (ASX: AVH) has commenced what it calls a “pivotal trial” for the treatment of paediatric scald injuries, seeking to demonstrate that its RECELL treatment can safely and effectively increase the incidence of healing when compared to a standard wound dressing. The new study is Avita’s second in as many days after […]